Serum levels of breast epithelial antigens (BrE-Ags) are presently used in the follow-up of breast cancer patients. Available assays do not have optimal sensitivity and rely on reagents that could vary in their source and purity. A novel competitive solid-phase radioimmunoassay was developed for BrE-Ags that consists of the NP5 fusion protein, produced in Escherichia coli, that is composed of beta-galactosidase and polypeptide sequence obtained from a breast carcinoma cell line cDNA library, and anti-human milk fat globule monoclonal antibody Mc5. The fusion protein carries an altered epitope sequence (mimotope) that is similar, but not identical, to that found in the native antigen. This new competitive assay configuration has two essential features, a solid-phase affinity step that purifies the fusion protein carrying the mimotope for Mc5 and a competitive step that provides quantitation. Serum values for this assay show high specificity and sensitivity for breast cancer patients when compared to normal subjects and post-surgical breast cancer patients during their disease-free period.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0003-2697(92)90192-a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and validation of transcriptome-wide association study-derived genes as potential druggable targets for osteoarthritis.
Bone Joint Res
March 2025
Department of Orthopedics, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China.
Aims: Osteoarthritis (OA) is a widespread chronic degenerative joint disease with an increasing global impact. The pathogenesis of OA involves complex interactions between genetic and environmental factors. Despite this, the specific genetic mechanisms underlying OA remain only partially understood, hindering the development of targeted therapeutic strategies.
View Article and Find Full Text PDFNovel insights into human CRISP2: localization in reproductive tissues and sperm, and molecular characterization.
Biol Reprod
March 2025
Cell Biology Laboratory, Research Institute for Biosciences, Research Institute for Health Sciences and Technology, University of Mons, Mons, Belgium.
CRISP2 is enriched in the male reproductive system of mammals and plays roles in spermatogenesis, sperm motility, and fertilization. Although extensively investigated in rodents and boars, human CRISP2 (hCRISP2) remains poorly studied, particularly concerning its localization in testicular and epididymal tissues and its molecular features. In this study, we used immunofluorescence to determine the localization of hCRISP2 in testis, epididymis, and ejaculated sperm.
View Article and Find Full Text PDFMaplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy.
Front Immunol
March 2025
Pfizer Oncology, Pfizer Inc., La Jolla, CA, United States.
Introduction: CD47 is highly expressed on cancer cells and triggers an anti-phagocytic "don't eat me" signal when bound by the inhibitory signal regulatory protein α (SIRPα) expressed on macrophages. While CD47 blockade can mitigate tumor growth, many CD47 blockers also bind to red blood cells (RBCs), leading to anemia. Maplirpacept (TTI-622, PF-07901801) is a CD47 blocking fusion protein consisting of a human SIRPα fused to an IgG4 Fc region and designed to limit binding to RBCs.
View Article and Find Full Text PDFEffect of active immunization with recombinant GnRH6-kisspeptin fusion protein on reproductive function in male rats.
Zygote
March 2025
1Department of Animal Veterinary Science, College of Animal Science and Technology, Anhui Agricultural University, Hefei, Anhui, China.
Immunological castration can be an alternative to traditional surgical castration. The active immunization against GnRH or kisspeptin has a castrating effect. To date, the fusion protein vaccine of combination with GnRH and kisspeptin have not been studied.
View Article and Find Full Text PDFArcyriaflavin A Alleviates Osteoporosis by Suppressing RANKL-Induced Osteoclastogenesis.
Int J Mol Sci
February 2025
Department of Orthopedics and Trauma Surgery, University Hospital Bonn, 53127 Bonn, Germany.
Osteoclasts (OCs) are important therapeutic targets in the treatment of osteoporosis. The aim of this study was to explore a novel therapeutic approach for osteoporosis using Arcyriaflavin A (ArcyA), a natural compound derived from the marine invertebrate sp. We systematically evaluated the effects of ArcyA on OC differentiation and function in mouse models using molecular biology assays, cellular function analyses and in vivo animal experiments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!